Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA GEL 0415 cutaneous leishmaniasis trial
RBR-4ypn69Phase 3Not yet recruiting
- Sponsor
- BNDES
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paromomycin and meglumine antimoniate in cutaneous leishmaniasis (CL) (2 arms), sponsored by BNDES. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
paromomycinmeglumine antimoniate
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on RBR-4ypn69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-4ypn69.